ARTICLE | Clinical News
Surfaxin lucinactant: Began Phase III trial
January 31, 2000 8:00 AM UTC
Discovery Laboratories Inc. (DSCO), Doylestown, Penn. Product: Surfaxin lucinactant Business: Pulmonary Therapeutic category: Oxygenation Target: Bronchial epithelial cells Description: KL4 sinapulti...